precisionmedicineonline4h
Tessellate Bio Partners With Australian Research Institutes to Study ALT-Driven Cancers
The collaboration will focus on researching the prevalence of ALT in cancer and its genetic drivers to develop new treatments.
precisionmedicineonline4h
Tesselate Bio Partners With Australian Research Institutes to Study ALT-Driven Cancers
The collaboration will focus on researching the prevalence of ALT in cancer and its genetic drivers to develop new treatments.
precisionmedicineonline6h
Prime Medicine Pipeline Prioritization, Licensing Deal With BMS to Fund Operations Into 2026
The firm is focusing on hematology, immunology, and oncology, liver, and lung conditions, while seeking partnerships beyond these core areas.
precisionmedicineonline7h
BioAI, Arbele Team up to Develop AI-Based Biomarker Screening Test
The companies will initially develop an AI-based test to select patients with CDH17-expressing gastrointestinal cancers for Arbele's Phase I drug trial.